Evidence map›Paper›PMID 41821758›Full record

ArticleFrontiers in toxicology2026

A comparison of honeybee and scorpion venoms as anticancer agents against three different cancer cell lines: lung, colon, and breast cancer.

Fatma H Galal, Fahad M Alshammari, Abdulrahman S Aldaghmi, Elsayed E Hafez, Ghada M El-Sayed, Riyadh H Aeban, Saad A Alharbi

Abstract read
In one paragraph

Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatma H GalalDepartment of Biology, College of Science, Jouf University, Sakaka, Aljouf, Saudi Arabia.
Fahad M AlshammariDepartment of Biology, College of Science, Jouf University, Sakaka, Aljouf, Saudi Arabia.
Abdulrahman S AldaghmiDepartment of Biology, College of Science, Jouf University, Sakaka, Aljouf, Saudi Arabia.
Elsayed E HafezPlant Protection and Biomolecular Diagnosis Department, ALCRI, City of Scientific Research and Technological Applications, Alexandria, Egypt.
Ghada M El-SayedMicrobial Genetic Department, Biotechnology Research Institute, National Research Centre, Cairo, Egypt.
Riyadh H AebanDepartment of Medical Molecular Laboratory, Security Forces Hospital Makkah, Makkah, Saudi Arabia.
Saad A AlharbiDepartment of Medical Molecular Laboratory, Security Forces Hospital Makkah, Makkah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to the drawbacks and adverse effects associated with conventional cancer therapies, there is growing interest in identifying effective natural alternatives. In this study, the anticancer potential of honeybee and scorpion venoms was evaluated using three human cancer cell lines: lung adenocarcinoma (A549), colon carcinoma (HCT-116), and breast adenocarcinoma (MDA-MB-231). The chemical composition, biological activity, and molecular interactions of both venoms with key cancer-related targets were investigated through gas chromatography-mass spectrometry (GC-MS), cytotoxicity assays, gene expression analysis, and molecular docking. GC-MS analysis revealed that scorpion venom was predominantly composed of methyl isocyanide, 3-butyn-1-ol, and allene, whereas honeybee venom was characterized by caprylic anhydride, 1,3,5-triazine derivatives, and palmitin as major bioactive constituents. Functional analyses demonstrated that both venoms modulated the expression of genes associated with apoptosis and other cancer-related pathways rather than inducing apoptosis directly. Notably, scorpion venom significantly downregulated the anti-apoptotic gene

Indexed as

anticancer markersbee venomGC-MSgene expressionmolecular dockingscorpion venom

Identifiers

PMID41821758
PMCPMC12975568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.